Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 380

1.

Fibroblast as a critical stromal cell type determining prognosis in prostate cancer.

Blom S, Erickson A, Östman A, Rannikko A, Mirtti T, Kallioniemi O, Pellinen T.

Prostate. 2019 Jul 3. doi: 10.1002/pros.23867. [Epub ahead of print]

PMID:
31269283
2.

Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML.

Karjalainen R, Liu M, Kumar A, He L, Malani D, Parsons A, Kontro M, Kallioniemi O, Porkka K, Heckman CA.

Leukemia. 2019 Jun 7. doi: 10.1038/s41375-019-0504-y. [Epub ahead of print] No abstract available.

PMID:
31175323
3.

Individual and stable autoantibody repertoires in healthy individuals.

Neiman M, Hellström C, Just D, Mattsson C, Fagerberg L, Schuppe-Koistinen I, Gummesson A, Bergström G, Kallioniemi O, Achour A, Sallinen R, Uhlén M, Nilsson P.

Autoimmunity. 2019 Feb;52(1):1-11. doi: 10.1080/08916934.2019.1581774. Epub 2019 Mar 5.

PMID:
30835561
4.

Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas.

Brodin BA, Wennerberg K, Lidbrink E, Brosjö O, Potdar S, Wilson JN, Ma L, Moens LN, Hesla A, Porovic E, Bernhardsson E, Papakonstantinou A, Bauer H, Tsagkozis P, von Sivers K, Wejde J, Östling P, Kallioniemi O, Stragliotto CL.

Br J Cancer. 2019 Feb;120(4):435-443. doi: 10.1038/s41416-018-0359-4. Epub 2019 Feb 12.

PMID:
30745580
5.

Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL.

Hohtari H, Brück O, Blom S, Turkki R, Sinisalo M, Kovanen PE, Kallioniemi O, Pellinen T, Porkka K, Mustjoki S.

Leukemia. 2019 Jul;33(7):1570-1582. doi: 10.1038/s41375-018-0360-1. Epub 2019 Jan 11.

PMID:
30635636
6.

Anagrelide for Gastrointestinal Stromal Tumor.

Pulkka OP, Gebreyohannes YK, Wozniak A, Mpindi JP, Tynninen O, Icay K, Cervera A, Keskitalo S, Murumägi A, Kulesskiy E, Laaksonen M, Wennerberg K, Varjosalo M, Laakkonen P, Lehtonen R, Hautaniemi S, Kallioniemi O, Schöffski P, Sihto H, Joensuu H.

Clin Cancer Res. 2019 Mar 1;25(5):1676-1687. doi: 10.1158/1078-0432.CCR-18-0815. Epub 2018 Dec 7.

PMID:
30530703
7.

Characterization of farnesyl diphosphate farnesyl transferase 1 (FDFT1) expression in cancer.

Tüzmen Ş, Hostetter G, Watanabe A, Ekmekçi C, Carrigan PE, Shechter I, Kallioniemi O, Miller LJ, Mousses S.

Per Med. 2019 Jan;16(1):51-65. doi: 10.2217/pme-2016-0058. Epub 2018 Nov 23.

PMID:
30468409
8.

Combined epithelial marker analysis of tumour budding in stage II colorectal cancer.

Slik K, Blom S, Turkki R, Välimäki K, Kurki S, Mustonen H, Haglund C, Carpén O, Kallioniemi O, Korkeila E, Sundström J, Pellinen T.

J Pathol Clin Res. 2019 Jan;5(1):63-78. doi: 10.1002/cjp2.119. Epub 2018 Nov 29.

9.

T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.

Leivonen SK, Pollari M, Brück O, Pellinen T, Autio M, Karjalainen-Lindsberg ML, Mannisto S, Kellokumpu-Lehtinen PL, Kallioniemi O, Mustjoki S, Leppä S.

Haematologica. 2019 Feb;104(2):338-346. doi: 10.3324/haematol.2018.200105. Epub 2018 Sep 20.

10.

Association of tamoxifen resistance and lipid reprogramming in breast cancer.

Hultsch S, Kankainen M, Paavolainen L, Kovanen RM, Ikonen E, Kangaspeska S, Pietiäinen V, Kallioniemi O.

BMC Cancer. 2018 Aug 24;18(1):850. doi: 10.1186/s12885-018-4757-z.

11.

Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells.

Saeed K, Ojamies P, Pellinen T, Eldfors S, Turkki R, Lundin J, Järvinen P, Nisen H, Taari K, Af Hällström TM, Rannikko A, Mirtti T, Kallioniemi O, Östling P.

Int J Cancer. 2019 Mar 15;144(6):1356-1366. doi: 10.1002/ijc.31815. Epub 2018 Nov 4.

PMID:
30125350
12.

PD-L1+ tumor-associated macrophages and PD-1+ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma.

Pollari M, Brück O, Pellinen T, Vähämurto P, Karjalainen-Lindsberg ML, Mannisto S, Kallioniemi O, Kellokumpu-Lehtinen PL, Mustjoki S, Leivonen SK, Leppä S.

Haematologica. 2018 Nov;103(11):1908-1914. doi: 10.3324/haematol.2018.197194. Epub 2018 Jul 19.

13.

Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy.

Lepikhova T, Karhemo PR, Louhimo R, Yadav B, Murumägi A, Kulesskiy E, Kivento M, Sihto H, Grénman R, Syrjänen SM, Kallioniemi O, Aittokallio T, Wennerberg K, Joensuu H, Monni O.

Mol Cancer Ther. 2018 Sep;17(9):2060-2071. doi: 10.1158/1535-7163.MCT-17-0733. Epub 2018 Jul 3.

PMID:
29970484
14.

Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML.

Brück O, Blom S, Dufva O, Turkki R, Chheda H, Ribeiro A, Kovanen P, Aittokallio T, Koskenvesa P, Kallioniemi O, Porkka K, Pellinen T, Mustjoki S.

Leukemia. 2018 Jul;32(7):1643-1656. doi: 10.1038/s41375-018-0175-0. Epub 2018 Jun 20.

PMID:
29925907
15.

Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.

Bruun J, Sveen A, Barros R, Eide PW, Eilertsen I, Kolberg M, Pellinen T, David L, Svindland A, Kallioniemi O, Guren MG, Nesbakken A, Almeida R, Lothe RA.

Mol Oncol. 2018 Sep;12(9):1639-1655. doi: 10.1002/1878-0261.12347. Epub 2018 Aug 15.

16.

Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia.

Ojamies PN, Kontro M, Edgren H, Ellonen P, Heckman C, Porkka K, Wolf M, Kallioniemi O.

Leuk Lymphoma. 2018 Dec;59(12):3002-3005. doi: 10.1080/10428194.2018.1453067. Epub 2018 Apr 4. No abstract available.

PMID:
29616861
17.

Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from Kras-driven lung tumours.

Närhi K, Nagaraj AS, Parri E, Turkki R, van Duijn PW, Hemmes A, Lahtela J, Uotinen V, Mäyränpää MI, Salmenkivi K, Räsänen J, Linder N, Trapman J, Rannikko A, Kallioniemi O, Af Hällström TM, Lundin J, Sommergruber W, Anders S, Verschuren EW.

J Pathol. 2018 May;245(1):101-113. doi: 10.1002/path.5059. Epub 2018 Apr 2. Erratum in: J Pathol. 2019 Jan;247(1):147.

18.

ITGB1-dependent upregulation of Caveolin-1 switches TGFβ signalling from tumour-suppressive to oncogenic in prostate cancer.

Pellinen T, Blom S, Sánchez S, Välimäki K, Mpindi JP, Azegrouz H, Strippoli R, Nieto R, Vitón M, Palacios I, Turkki R, Wang Y, Sánchez-Alvarez M, Nordling S, Bützow A, Mirtti T, Rannikko A, Montoya MC, Kallioniemi O, Del Pozo MA.

Sci Rep. 2018 Feb 5;8(1):2338. doi: 10.1038/s41598-018-20161-2.

19.

Clinical relevance of integrin alpha 4 in gastrointestinal stromal tumours.

Pulkka OP, Mpindi JP, Tynninen O, Nilsson B, Kallioniemi O, Sihto H, Joensuu H.

J Cell Mol Med. 2018 Apr;22(4):2220-2230. doi: 10.1111/jcmm.13502. Epub 2018 Jan 29.

20.

Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.

Karvonen H, Chiron D, Niininen W, Ek S, Jerkeman M, Moradi E, Nykter M, Heckman CA, Kallioniemi O, Murumägi A, Ungureanu D.

Blood Adv. 2017 Nov 9;1(24):2257-2268. doi: 10.1182/bloodadvances.2017010215. eCollection 2017 Nov 14.

21.

Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.

Sveen A, Bruun J, Eide PW, Eilertsen IA, Ramirez L, Murumägi A, Arjama M, Danielsen SA, Kryeziu K, Elez E, Tabernero J, Guinney J, Palmer HG, Nesbakken A, Kallioniemi O, Dienstmann R, Lothe RA.

Clin Cancer Res. 2018 Feb 15;24(4):794-806. doi: 10.1158/1078-0432.CCR-17-1234. Epub 2017 Dec 14.

22.

Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis.

Blom S, Paavolainen L, Bychkov D, Turkki R, Mäki-Teeri P, Hemmes A, Välimäki K, Lundin J, Kallioniemi O, Pellinen T.

Sci Rep. 2017 Nov 14;7(1):15580. doi: 10.1038/s41598-017-15798-4.

23.

Metabolomic Profiling of Extracellular Vesicles and Alternative Normalization Methods Reveal Enriched Metabolites and Strategies to Study Prostate Cancer-Related Changes.

Puhka M, Takatalo M, Nordberg ME, Valkonen S, Nandania J, Aatonen M, Yliperttula M, Laitinen S, Velagapudi V, Mirtti T, Kallioniemi O, Rannikko A, Siljander PR, Af Hällström TM.

Theranostics. 2017 Aug 23;7(16):3824-3841. doi: 10.7150/thno.19890. eCollection 2017.

24.

The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia.

Kumar A, Kankainen M, Parsons A, Kallioniemi O, Mattila P, Heckman CA.

BMC Genomics. 2017 Aug 17;18(1):629. doi: 10.1186/s12864-017-4039-1.

25.

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Andersson EI, Pützer S, Yadav B, Dufva O, Khan S, He L, Sellner L, Schrader A, Crispatzu G, Oleś M, Zhang H, Adnan-Awad S, Lagström S, Bellanger D, Mpindi JP, Eldfors S, Pemovska T, Pietarinen P, Lauhio A, Tomska K, Cuesta-Mateos C, Faber E, Koschmieder S, Brümmendorf TH, Kytölä S, Savolainen ER, Siitonen T, Ellonen P, Kallioniemi O, Wennerberg K, Ding W, Stern MH, Huber W, Anders S, Tang J, Aittokallio T, Zenz T, Herling M, Mustjoki S.

Leukemia. 2018 Mar;32(3):774-787. doi: 10.1038/leu.2017.252. Epub 2017 Aug 14.

PMID:
28804127
26.

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.

Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, Yadav B, Tamborero D, Tang J, Bychkov D, Kontro M, Parsons A, Suvela M, Mayoral Safont M, Porkka K, Aittokallio T, Kallioniemi O, McCormack E, Gjertsen BT, Wennerberg K, Knowles J, Heckman CA.

Blood. 2017 Aug 10;130(6):789-802. doi: 10.1182/blood-2016-02-699363. Epub 2017 Jun 15.

27.

Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.

Kolberg M, Bruun J, Murumägi A, Mpindi JP, Bergsland CH, Høland M, Eilertsen IA, Danielsen SA, Kallioniemi O, Lothe RA.

Mol Oncol. 2017 Sep;11(9):1156-1171. doi: 10.1002/1878-0261.12086. Epub 2017 Jul 5.

28.

PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells.

Lehtinen L, Vainio P, Wikman H, Huhtala H, Mueller V, Kallioniemi A, Pantel K, Kronqvist P, Kallioniemi O, Carpèn O, Iljin K.

J Pathol Clin Res. 2017 Apr 4;3(2):123-138. doi: 10.1002/cjp2.69. eCollection 2017 Apr.

29.

Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response.

Jernström S, Hongisto V, Leivonen SK, Due EU, Tadele DS, Edgren H, Kallioniemi O, Perälä M, Mælandsmo GM, Sahlberg KK.

Breast Cancer (Dove Med Press). 2017 Mar 21;9:185-198. doi: 10.2147/BCTT.S115600. eCollection 2017.

30.

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.

Pietarinen PO, Eide CA, Ayuda-Durán P, Potdar S, Kuusanmäki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, Tyner JW, Mustjoki S, Porkka K.

Oncotarget. 2017 Apr 4;8(14):22606-22615. doi: 10.18632/oncotarget.15146.

31.

Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells.

Haltia UM, Andersson N, Yadav B, Färkkilä A, Kulesskiy E, Kankainen M, Tang J, Bützow R, Riska A, Leminen A, Heikinheimo M, Kallioniemi O, Unkila-Kallio L, Wennerberg K, Aittokallio T, Anttonen M.

Gynecol Oncol. 2017 Mar;144(3):621-630. doi: 10.1016/j.ygyno.2016.12.016. Epub 2017 Jan 16.

PMID:
28104295
32.

Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1.

Nagaraj AS, Lahtela J, Hemmes A, Pellinen T, Blom S, Devlin JR, Salmenkivi K, Kallioniemi O, Mäyränpää MI, Närhi K, Verschuren EW.

Cell Rep. 2017 Jan 17;18(3):673-684. doi: 10.1016/j.celrep.2016.12.059.

33.

Consistency in drug response profiling.

Mpindi JP, Yadav B, Östling P, Gautam P, Malani D, Murumägi A, Hirasawa A, Kangaspeska S, Wennerberg K, Kallioniemi O, Aittokallio T.

Nature. 2016 Nov 30;540(7631):E5-E6. doi: 10.1038/nature20171. No abstract available.

PMID:
27905421
34.

High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer.

Ketola K, Viitala M, Kohonen P, Fey V, Culig Z, Kallioniemi O, Iljin K.

J Mol Biochem. 2016 Mar 30;5(1):12-22.

35.

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.

Malani D, Murumägi A, Yadav B, Kontro M, Eldfors S, Kumar A, Karjalainen R, Majumder MM, Ojamies P, Pemovska T, Wennerberg K, Heckman C, Porkka K, Wolf M, Aittokallio T, Kallioniemi O.

Leukemia. 2017 May;31(5):1187-1195. doi: 10.1038/leu.2016.314. Epub 2016 Nov 11.

36.

Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia.

Ojamies PN, Kontro M, Edgren H, Ellonen P, Lagström S, Almusa H, Miettinen T, Eldfors S, Tamborero D, Wennerberg K, Heckman C, Porkka K, Wolf M, Kallioniemi O.

Leukemia. 2017 May;31(5):1048-1058. doi: 10.1038/leu.2016.286. Epub 2016 Oct 31.

PMID:
27795554
37.

KeepEX, a simple dilution protocol for improving extracellular vesicle yields from urine.

Puhka M, Nordberg ME, Valkonen S, Rannikko A, Kallioniemi O, Siljander P, Af Hällström TM.

Eur J Pharm Sci. 2017 Feb 15;98:30-39. doi: 10.1016/j.ejps.2016.10.021. Epub 2016 Oct 19.

PMID:
27771514
38.

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.

Brunen D, García-Barchino MJ, Malani D, Jagalur Basheer N, Lieftink C, Beijersbergen RL, Murumägi A, Porkka K, Wolf M, Zwaan CM, Fornerod M, Kallioniemi O, Martínez-Climent JÁ, Bernards R.

Oncotarget. 2016 Jun 21;7(25):37407-37419. doi: 10.18632/oncotarget.9822.

39.

Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization.

Ammad-Ud-Din M, Khan SA, Malani D, Murumägi A, Kallioniemi O, Aittokallio T, Kaski S.

Bioinformatics. 2016 Sep 1;32(17):i455-i463. doi: 10.1093/bioinformatics/btw433.

PMID:
27587662
40.

HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.

Kontro M, Kumar A, Majumder MM, Eldfors S, Parsons A, Pemovska T, Saarela J, Yadav B, Malani D, Fløisand Y, Höglund M, Remes K, Gjertsen BT, Kallioniemi O, Wennerberg K, Heckman CA, Porkka K.

Leukemia. 2017 Feb;31(2):301-309. doi: 10.1038/leu.2016.222. Epub 2016 Aug 8.

PMID:
27499136
41.

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia.

Eldfors S, Kuusanmäki H, Kontro M, Majumder MM, Parsons A, Edgren H, Pemovska T, Kallioniemi O, Wennerberg K, Gökbuget N, Burmeister T, Porkka K, Heckman CA.

Leukemia. 2017 Jan;31(1):51-57. doi: 10.1038/leu.2016.202. Epub 2016 Jul 27.

42.

Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.

Kangaspeska S, Hultsch S, Jaiswal A, Edgren H, Mpindi JP, Eldfors S, Brück O, Aittokallio T, Kallioniemi O.

BMC Cancer. 2016 Jul 4;16:378. doi: 10.1186/s12885-016-2452-5.

43.

Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer.

Saeed K, Rahkama V, Eldfors S, Bychkov D, Mpindi JP, Yadav B, Paavolainen L, Aittokallio T, Heckman C, Wennerberg K, Peehl DM, Horvath P, Mirtti T, Rannikko A, Kallioniemi O, Östling P, Af Hällström TM.

Eur Urol. 2017 Mar;71(3):319-327. doi: 10.1016/j.eururo.2016.04.019. Epub 2016 May 6.

44.

A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability.

Cantisani MC, Parascandolo A, Perälä M, Allocca C, Fey V, Sahlberg N, Merolla F, Basolo F, Laukkanen MO, Kallioniemi OP, Santoro M, Castellone MD.

Oncotarget. 2016 May 10;7(19):28510-22. doi: 10.18632/oncotarget.8577.

45.

Oncogenic Herpesvirus Utilizes Stress-Induced Cell Cycle Checkpoints for Efficient Lytic Replication.

Balistreri G, Viiliäinen J, Turunen M, Diaz R, Lyly L, Pekkonen P, Rantala J, Ojala K, Sarek G, Teesalu M, Denisova O, Peltonen K, Julkunen I, Varjosalo M, Kainov D, Kallioniemi O, Laiho M, Taipale J, Hautaniemi S, Ojala PM.

PLoS Pathog. 2016 Feb 18;12(2):e1005424. doi: 10.1371/journal.ppat.1005424. eCollection 2016 Feb.

46.

Relevance Rank Platform (RRP) for Functional Filtering of High Content Protein-Protein Interaction Data.

Pokharel YR, Saarela J, Szwajda A, Rupp C, Rokka A, Lal Kumar Karna S, Teittinen K, Corthals G, Kallioniemi O, Wennerberg K, Aittokallio T, Westermarck J.

Mol Cell Proteomics. 2015 Dec;14(12):3274-83. doi: 10.1074/mcp.M115.050773. Epub 2015 Oct 23.

47.

Systematic Identification of MicroRNAs That Impact on Proliferation of Prostate Cancer Cells and Display Changed Expression in Tumor Tissue.

Aakula A, Kohonen P, Leivonen SK, Mäkelä R, Hintsanen P, Mpindi JP, Martens-Uzunova E, Aittokallio T, Jenster G, Perälä M, Kallioniemi O, Östling P.

Eur Urol. 2016 Jun;69(6):1120-8. doi: 10.1016/j.eururo.2015.09.019. Epub 2015 Oct 20.

PMID:
26489476
48.

Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose-response data.

Mpindi JP, Swapnil P, Dmitrii B, Jani S, Saeed K, Wennerberg K, Aittokallio T, Östling P, Kallioniemi O.

Bioinformatics. 2015 Dec 1;31(23):3815-21. doi: 10.1093/bioinformatics/btv455. Epub 2015 Aug 7.

49.

Circulating tumor DNA in early-stage breast cancer: personalized biomarkers for occult metastatic disease and risk of relapse?

af Hällström TM, Puhka M, Kallioniemi O.

EMBO Mol Med. 2015 Aug;7(8):994-5. doi: 10.15252/emmm.201505332.

50.

The impact of low-frequency and rare variants on lipid levels.

Surakka I, Horikoshi M, Mägi R, Sarin AP, Mahajan A, Lagou V, Marullo L, Ferreira T, Miraglio B, Timonen S, Kettunen J, Pirinen M, Karjalainen J, Thorleifsson G, Hägg S, Hottenga JJ, Isaacs A, Ladenvall C, Beekman M, Esko T, Ried JS, Nelson CP, Willenborg C, Gustafsson S, Westra HJ, Blades M, de Craen AJ, de Geus EJ, Deelen J, Grallert H, Hamsten A, Havulinna AS, Hengstenberg C, Houwing-Duistermaat JJ, Hyppönen E, Karssen LC, Lehtimäki T, Lyssenko V, Magnusson PK, Mihailov E, Müller-Nurasyid M, Mpindi JP, Pedersen NL, Penninx BW, Perola M, Pers TH, Peters A, Rung J, Smit JH, Steinthorsdottir V, Tobin MD, Tsernikova N, van Leeuwen EM, Viikari JS, Willems SM, Willemsen G, Schunkert H, Erdmann J, Samani NJ, Kaprio J, Lind L, Gieger C, Metspalu A, Slagboom PE, Groop L, van Duijn CM, Eriksson JG, Jula A, Salomaa V, Boomsma DI, Power C, Raitakari OT, Ingelsson E, Järvelin MR, Thorsteinsdottir U, Franke L, Ikonen E, Kallioniemi O, Pietiäinen V, Lindgren CM, Stefansson K, Palotie A, McCarthy MI, Morris AP, Prokopenko I, Ripatti S; ENGAGE Consortium.

Nat Genet. 2015 Jun;47(6):589-97. doi: 10.1038/ng.3300. Epub 2015 May 11.

Supplemental Content

Loading ...
Support Center